SCIENTIFIC PLATFORM
Functional immune interaction decoding platform
BNX-IFS™ is a functional immune analysis platform that quantitatively detects and interprets cell-cell interaction states centered on activated T cells.
Beyond conventional static immune phenotyping, this platform introduces a new analytical framework in which functional interaction states between immune cells themselves become the primary unit of analysis.
- Functional immune signal detection
- Cell-cell interaction mapping
- Biomarker discovery and patient stratification
- Mechanism-of-action clarification
- Immune modulation guidance
BIOLOGICAL FOUNDATION
Functional immune regulation beyond the tumor microenvironment
The success of cancer immunotherapy is determined not only by the tumor microenvironment but also by the host immune condition. In particular, immune regulation acting after TCR activation can determine whether productive T-cell expansion is sustained and whether anti-tumor immunity is maintained or suppressed.
Bionoxx identified a regulatory mechanism in which neutrophils modulate post-activation T-cell responses through multi-layer cell-cell interactions, and demonstrated that this biology can be quantitatively analyzed using BNX-IFS™.
This biology provides the foundation for a new therapeutic strategy to restore anti-tumor T-cell activity and overcome resistance to immune checkpoint inhibitors.
TRANSLATIONAL APPLICATION
Platform-driven host immune modulation
BNX-IFS™ functions not only as an analytical platform but also as a translational engine.
It enables functional immune-state assessment, prediction of therapeutic response, design of immune modulation strategies, and discovery of clinical biomarkers.
This approach is being applied to OTS-412/HU-based oncolytic virotherapy to rebalance host immune regulation and restore productive T-cell–dominant anti-tumor immunity.
CLINICAL PROGRAM
Platform-guided clinical development
Bionoxx is advancing clinical-stage programs under regulatory approval in the United States and Korea. These studies are designed not only for safety evaluation but also to define immune signals based on functional immune interactions.
BNX-IFS™ is being used to quantitatively assess immune reprogramming signals, restoration of T-cell responses, and host immune modulation dynamics in clinical samples.
COLLABORATION
BNX-IFS™–Guided Asset Qualification for Strategic Partnership
Bionoxx provides a BNX-IFS™-guided pre-partnering validation program to evaluate partner assets within a functional immune interaction framework.
Partner candidates are assessed for their ability to modulate host immune interaction states associated with productive T-cell responses.
- Early identification of immune-active assets
- Functional biomarker discovery
- Mechanism-of-action clarification
- Patient selection strategy development
- Translational validation prior to partnership
The resulting data package supports go/no-go decisions and structured progression toward strategic collaboration or co-development agreements.
TEAM & INFRASTRUCTURE
Translational immunology leadership
Bionoxx’s work is built on more than 23 years of translational research in oncolytic virotherapy.
We combine physician-scientist leadership, translational immunology expertise, a GCLP-designated laboratory, and GMP-grade quality assessment infrastructure to support functional immune analysis in clinical samples.
CONTACT
Partnership and investment
Bionoxx welcomes collaboration with partners and investors to advance next-generation immune modulation strategies based on functional immune interaction biology.
Collaboration | Strategic partnership | Investment
Strategic partnership inquiries:
thhwang@bionoxx.com